Need Public Policy for Human Gene Editing, Heatwaves, or Asteroids? Try Thinking Like a Citizen
By Nicholas Weller, Michelle Sullivan Govani, Mahmud Farooque,
Issues in Science and Technology
| 05. 19. 2021
In a ballroom at the Arizona Science Center one afternoon in 2017, more than 70 Phoenix residents—students, teachers, nurses, and retirees—gathered around tables to participate in a public forum about how cities can respond to extreme weather such as heat waves. Each table was covered in colorful printouts with a large laminated poster resembling a board game. Milling between the tables were decisionmakers from local government and the state. All were taking part in a deliberative process called participatory technology assessment, or pTA, designed to break down the walls between “experts” and citizens to gain insights into public policy dilemmas involving science, technology, and uncertainty.
Foreshadowing their varied viewpoints and experiences, participants prepared differently for the “extreme weather” of the heavily air conditioned ballroom, with some gripping cardigans around their shoulders while others were comfortable in tank tops. Extreme heat is something all the participants were familiar with—Phoenix is one of the hottest cities in the country—but not everyone understood the unequal way that heat and related deaths affect different parts of the Valley of the Sun. Though a...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...